Kornimate/medical-research-clean huggingface dataset:
effect of a phosphate modified diet on phosphate balance and phosphate metabolism in predialysis patients stage 3-4

Conditions: Chronic Kidney Disease

Summary: patients with chronic kidney disease struggle to eliminate phosphate as the renal function deteriorates, which results in accumulation of phosphate in the body. this has been shown to increase the patients' risk of cardiovascular disease and death. even with dialysis treatment the patients cannot excrete enough phosphate to reach phosphate balance. the patients are therefore recommended a very restrictive diet when they reach the dialysis stage. it is therefore important to find ways to prevent such accumulation of phosphate in the body as early in the disease process as possible, but without compromising the nutritional status. because phosphate occurs naturally in many of our foods, such as meat, fish and dairy products, it is difficult to reduce the intake of phosphate, without also reducing the intake of energy and protein. over the past couple of years there has been an increased focus on the use of phosphate containing additives in the food industry. a reduction in the intake of phosphorus containing additives may reduce the accumulation of phosphate in the body. this can be achieved by decreasing the intake of processed food products. because it is also very time consuming and inconvenient for the patient to keep these strict diets, the patients have a reasonable claim to know which effects can be achieved by such diets. this will therefore seek to be further explored in the following study. the study is conducted as a randomised crossover trial in predialysis patients stage 3-4.


Eligibility criteria:
inclusion criteria: * patients \> 18 years. * diagnosed with chronic kidney disease stage 3-4 (gfr 15-59 ml / min) * p-phosphate between 0.85 mmol / l (2.7 mg / dl) and 1.50 mmol / l (4.7 mg / dl) * read and understand danish * have received oral and written information about the study * signed informed consent form exclusion criteria: * diagnosed hyperphosphatemia * diagnosed hyperparathyroidism * treatment with phosphate binders * dysphagia * diagnosed with decreased absorption capacity in the intestine * co-morbidities in liver, pancreas or lungs * dementia * pregnancy / breastfeeding * embedded within the last 4 weeks * kidney transplant * terminal patients
nobori and uncoated stent in coronary attack

Conditions: Acute Myocardial Infarction

Summary: drug-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. data are limited regarding the safety and efficacy of nobori (biolimus a9 eluting stent) in primary percutaneous coronary intervention (pci) for acute myocardial infarction (ami). accordingly, the investigators will compare the outcomes of primary pci for ami between patients receiving nobori versus uncoated stents.


Eligibility criteria:
inclusion criteria: * age more than 20 years old * chest pain lasting more than 20 min * symptoms beginning within 12 hours before characterization * electrocardiogram showing st-segment elevation or new appearance of left bundle branch block * increase in cardiac enzymes to more than 5-fold the normal laboratory values * infarct-related vessel are anatomically suitable for percutaneous revascularization * patients gave their signed, informed consent exclusion criteria: * previous stent implantation within 30 days * allergy to any of the followings : aspirin, heparin, clopidogrel, biolimus a9 or its derivatives, stainless steel 316l, pla (poly-lactic acid) polymer or its derivatives, and contrast media * elective surgery scheduled within 6 months * renal insufficiency with creatinine level of more than 2.5 mg/dl * patients associated with bleeding and/or clotting disorders, and those refusing blood transfusion * history of massive gastrointestinal or urinary tract bleeding within 6 months * patients currently enrolled in other clinical trials * pregnancy

Keywords: acute myocardial infarction stents angioplasty thrombosis
a double-blind, comparative study in patients with gastric ulcer to evaluate the efficacy of combination use of e0671 and rabeprazole sodium

Conditions: Stomach Ulcer

Summary: the purpose of this study is to investigate the efficacy and safety of combination use of e0671 and rabeprazole sodium in patients with gastric ulcer.

the efficacy and safety of e0671 in combination with rabeprazole sodium (i.e., 10 mg/day of rabeprazole sodium and 150 mg/day of e0671) will be investigated in patients with gastric ulcer in a multicenter, randomized, double-blind, parallel-group comparative study using a placebo control group (10 mg/day of rabeprazole sodium and placebo for e0671).

Eligibility criteria:
inclusion criteria: 1. patients with gastric ulcer (a1-and a2-stage) 2. patients with gastric ulcer who meet all of the following items. gender and treatment class (in-patient or out-patient) are not asked. * patients with endoscopically diagnosed a1- or a2-stage ulcer (by sakita/miwa classification). * patients who are not younger than 20 years of age at the time of obtaining informed consent. * patients who meet any of the following conditions: * h. pylori-negative * h. pylori-positive and not requiring eradication therapy * h. pylori-positive and unsuccessful eradication 3. patients who are given a full explanation about the study objective and design, and able to give prior consent for study participation. exclusion criteria: 1. patients with a complication of duodenal ulcer (excluding cicatrix). 2. patients with reflux esophagitis 3. patients with acute gastric mucosal lesions (agml). 4. patients with nsaid-induced ulcer. 5. patients with linear ulcer. 6. patients with ulcer injured by endoscopy. 7. patients who underwent gastrectomy or vagal nerve resection. 8. patients who are not applied to pharmacotherapy, i.e., perforation, pyloric stenosis, major bleeding (exposed blood vessels in the base of ulcer), etc. 9. patients receiving proton pump inhibitor (ppi) and/or teprenone preparation(s) within 1 week prior to the study administration. 10. patients with serious cardiovascular diseases (e.g., angina pectoris, heart failure, acute myocardial ischemia, severe tachyarrhythmia), serious hematological disorders (e.g., aplastic anemia), serious renal disorders (e.g., acute, chronic renal failure), serious hepatic disorders (e.g., cirrhosis, severe hepatitis), serious pancreatic disorders (e.g., severe pancreatitis), serious psychoneuroses (e.g., schizophrenia, alcoholic dependency, drug dependency, severe depression), or cancer. 11. patients with a current or a history of drug allergy to teprenone preparation(s). 12. patients with a current or a history of drug allergy to ppi. 13. patients requiring antacid(s) containing digoxin or aluminum hydroxide/magnesium hydroxide that are suspected to exert drug interaction with rabeprazole sodium.
wide area circular ablation versus extra-wide area circular ablation in persistent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: ablation of atrial fibrillation is an established method for treatment of subjects with atrial fibrillation with goal of restoration of sinus rhythm. among different methods, wide area circular ablation (waca) is shown to provide the same results with fewer complications. this project will compare waca with extra-wide area circular ablation (e-waca) in subjects who are considered for ablation of atrial fibrillation.


Eligibility criteria:
inclusion criteria: * all subjects with symptomatic persistent atrial fibrillation who are scheduled for clinically indicated ablation of af. exclusion criteria: * subjects younger than 18 year of age. * subjects who are pregnant. * subjects who are unable to provide consent.
assessment of safety and efficacy of im19 for recurrent or refractory (r/r) non-hodgkin's lymphoma(nhl) patients

Conditions: NHL

Summary: this is a phase i/ii, multicenter study to assess the efficacy and safety of im19 car-t cells in adult with r/r non-hodgkins lymphoma in china.

this is a phase ⅰ/ⅱ. the phase i is a single-center study. the main objective is to evaluate the safety of im19 car-t cell therapy for patients with relapsed or refractory cd19-positive invasion of non-hodgkin's lymphoma. the phase ⅱ is a multi-center study,the main goal is to evaluate the efficacy of im19 car-t cells in the treatment of patients with relapsed or refractory cd19-positive invasion of non-hodgkin's lymphoma.

Eligibility criteria:
inclusion criteria: * subjects with relapsed or refractory invasive non-hodgkin's lymphoma, confirmed by cd19 positive cytology or histology, specific types. * cd20 positive patients undergo corresponding targeted therapy. * patients must have evaluable evidence of disease (according to lugano 2014 standards). * ≥ 18 years old. * the expected survival period is more than 3 months. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * women of childbearing age have a negative blood pregnancy test before the start of the trial and agree to have effective contraceptive measures during the trial until the last follow-up * participate voluntarily in this experiment and sign the informed consent. exclusion criteria: * the investigators judged patients with gastrointestinal lymph nodes and/or central nervous system involvement who may be at risk for car-t treatment. * subject has graft-versus-host reactions and need to use immunosuppressants; or suffer from autoimmune disease * subject has used chemotherapy or radiotherapy within three days before the blood collection period. * subject has used systemic steroid drugs within 5 days before the blood collection period (except for recent or current inhaled steroids). * those who use drugs that stimulate bone marrow hematopoietic cells to produce drugs within 5 days before the blood collection * subject has used any gene therapy products before. * subject with a history of epilepsy or other central nervous system diseases. * active hepatitis b virus or hepatitis c virus infections * the subject with other tumors in the past 5 years. * within 14 days before enrollment, there was active infection or uncontrollable infection requiring systemic treatment.
a clinical study of subclinical enthesitis and synovitis in patients with vulgaris psoriasis

Conditions: Vulgaris Psoriasis

Summary: a clinical study of subclinical enthesitis and synovitis in patients with vulgaris psoriasis

a total of 100 patients with vulgaris psoriasis and 100 age-matched controls with other skin diseases, all without musculoskeletal diseases, will be recruited. they will undergo dermatological assessment and a blinded pdus evaluation. clinical assessment included demographics, severity of psoriasis, musculoskeletal clinical examination and sport activities. pdus evaluation consisted of the detection of grey scale (gs) synovitis and synovial pd signal in joints of extremities, gs enthesopathy and entheseal pd signal in entheses of lower limbs.

Eligibility criteria:
inclusion criteria: * age≥18years * patients with vulgaris psoriasis(dur * patients with other skin diseases without musculoskeletal disorders * no joint involvement and no clinical symptoms and signs of enthesitis and synovitis exclusion criteria: * bmi≥24 * have history of gout or arthritis or peripheral neurological disease of lower extremity or trauma * have received any systemic therapy(i.e.nsaids, corticosteroids, immunosuppressants, retinoids or biological agents) in 3 months * pregnant or breast-feeding

Keywords: subclinical, enthesitis, synovitis
population pharmacokinetics of l-amb in chinese patients assisted by extracorporeal membrane pulmonary oxygenation (ecmo)

Conditions: Invasive Fungal Infections; Liposomal Amphotericin B

Summary: the goal of this study is to investigate the effects of ecmo-assisted therapy on l-amb pk parameters in patients with critically ill patients of invasive fungal infections, and to determine the in vivo pharmacokinetic changes of l-amb in the ecmo population. to establish and validate a population pharmacokinetic model for liposomal amphotericin b in patients with critically ill patients of invasive fungal infections treated with ecmo adjuvant therapy, and to explore the pharmacokinetics/pharmacodynamics of the drug with different dosing regimens.

the information of patient characteristics, physiological parameters, ecmo related parameters, administration and sampling information of l-amb were collected.patients were intravenously titrated after 3 doses of maintenance dose titration. the sampling window was from 0 to 24 h. the time points were 0.5 h before and 1, 2, 3, 6, 9, 12, 16, 20 and 24 h after administration. nonmem software was applied to establish the ppk model of l-amb.

Eligibility criteria:
inclusion criteria: * diagnostic criteria for invasive fungal infections presenting to the intensive care unit (icu) with probable or proved patients according to the 2021 eortc/msgerc guideline. * requiring ecom assistance. * age 18 years. exclusion criteria: * intolerance of l-amb therapy. * pregnancy. * expected survival time \<24 hours. * lack of necessary data on patient demographics physiopathology, and clinical status.
analysis of respiration-induced deformations in visceral and renal arteries before and after stenting during branched stent treatment.

Conditions: Complex Aortic Aneurysms

Summary: aneurysm of the abdominal aorta is defined by a loss of parallelism of the arterial wall. the main risk of this pathology is the rupture of the aneurysm which is life threatening and this risk increases with the size of the aneurysm. connected stents allow the management of complex thoracoabdominal aneurysms in patients at high surgical risk and/or contraindicated for open surgery. these endovascular techniques have demonstrated their safety and efficacy, however, long-term ct follow-up remains essential to detect complications such as endo-leaks and restenosis/thrombosis of visceral and renal stents. the prognostic factors of these complications remain poorly elucidated. the type of stent to be used could be an explanation, however, no stent has been proven to be superior in this application to date. data from the literature suggest an influence of stents on the aortic geometry and the arterial axes of the digestive tract during respiratory movements. the work of the stanford vascular surgery team shows that the deformations and modifications of the geometry of these stents induced by the respiratory cycle could have a negative impact by migration, stenosis and thrombosis.


Eligibility criteria:
inclusion criteria: * no contre indication for coroscanner exclusion criteria: * pregnant woman * allergy to iodinated contrast media * vulnerable people
effects of a gum gel intended to treat signs and symptoms of teething

Conditions: Tooth Eruption Disorder

Summary: teething discomfort is a widespread disorder affecting a very high percentage of infants. the use of hyaluronic acid gels has been shown in the last 20 years to be an effective tool, generally devoid of side effects, in reducing oral mucosal inflammation in adults. its effectiveness in infants is affected by the strength of hyaluronic acid retention over the oral mucosa. this is in turn affected by formulation and may vary between different products due to the different ingredients used. in this study, the results collected by monitoring the paediatric experience regarding a newly developed ha-based medical device, intended to counteract teething discomfort in infants, will be reported.


Eligibility criteria:
inclusion criteria: * teething discomfort * being healthy (except for teething discomfort) exclusion criteria: * being placed on one of the following therapies in the 45 days prior to the beginning of the study: immunosuppressive, cytotoxic, cortisone, antibiotics, antifungal and hormone therapy

Keywords: gums redness fever paediatric inappetence sleep disturbance
effects of emicizumab vs. factor viii prophylaxis on joint and bone health in severe hemophilia a

Conditions: Hemophilia A

Summary: the investigators propose to study longitudinal joint and bone density changes in patients with severe hemophilia a. per current standard of care, most patients are on prophylactic fviii replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% fviii. recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. it is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compare the effect of routine factor viii prophylaxis with emicizumab prophylaxis.

summary: this retrospective/prospective, non-randomized controlled study, whereby patients will be included in 1 of 2 groups depending on their current treatments as outlined below. patients will be assigned to a specific group by the clinician/pi based on their current regimen with the intent to stay on this regimen for the next 3 years. duration of study and subject participation: study subject enrollment is anticipated to occur over about 12 months and study duration per subject will be 3 years. thus a total study duration of 4 years is anticipated. intervention: by using musculoskeletal ultrasound, the investigators will measure joint health among participants and assess joint health changes over 3 years compared between group a (factor prophylaxis) vs. group b (emicizumab prophylaxis) as assessed by mskus at baseline and after 3 years. other outcomes such as bone density, comparative assessment of joint and overall health status, and exploration of potential biomarkers for joint and bone health will also be assessed.

Eligibility criteria:
inclusion criteria: * male gender * severe hemophilia a (factor viii \< 1%) * age ≥ 16 year * either on prophylaxis with factor viii or emicizumab with the intention to stay on the current regimen for the next 3 years * willing and able to give written informed consent/assent * willing to undergo mskus, dexa scan +/- collection of blood sampling for repository biomarkers * willing to come in for baseline and 3 yearly visits * willing to answer phone survey for bleeding and safety every 3 months exclusion criteria: * current fviii inhibitor of \> 0.6 bu * unable to take fviii replacement * other known bleeding disorder * other rheumatologic disorder affecting joints * other known neuromotor defect (making physical exam difficult)

Keywords: hemophilia a joint health bone density emicizumab factor viii prophylaxis
impact of covid-19 on sinus augmentation surgery

Conditions: Bone Loss

Summary: the risk of schneiderian membrane perforation and the postoperative complications of the sinus floor elevation surgery were evaluated for patients with and without history of covid-19 infection.

covid-19 induced chronic sinusitis with subsequent increased schneiderian membrane thickness could increase the risk of its perforation during the sinus floor elevation. the aim of the study is to compare the incidence of schneiderian membrane perforation and the postoperive complications of the sinus floor elevation in patients with and without history of covid-19.

Eligibility criteria:
inclusion criteria: * 4 mm or less residual alveolar bone height * age more than 18 years * highly motivated patients exclusion criteria: * patients who suffer from any systemic disease * sinus pathosis other than sinusitis induced covid 19 * patients under any medication that may interfere with the normal bone healing
effect of leg pedalling exercise from inclined position

Conditions: Cerebral Palsy Spastic Diplegia

Summary: statement of the problem:- does the lower limb pedalling exercise from inclined position improve functional ability and trunk control in children with diplegic cerebral palsy? null hypothesis:- there will be no effect of lower limb pedalling exercise from inclined position on functional ability and trunk control in children with diplegic cerebral palsy

subjects a convenient sample of children diagnosed as spastic diplegic cerebral palsy (cp) from both sexes will be recruited based on a pilot study according to the inclusion and exclusion criteria. they will be selected from the out-patient private clinics in giza and tenth of ramadan city. study design: randomized controlled clinical trial. children will receive intervention type randomly, 15 child received the designed physical therapy program and the pedaling exercise from inclined position and the other 15 child receieved the designed physical therapy program only. children will be assessed by measuring functional ability with gross motor functional measures and trunk control with trunk control measurement scale

Eligibility criteria:
inclusion criteria: .age ranges from 6-9 years. .grade 1, 1+ of the modified ashworth scale. .level ii, iii according to gross motorfunctional classification system (gmfcs). .able to pedal independently on a static bicycle. .ability to follow command. exclusion criteria: .significant visual or auditory impairments. .structural or fixed deformities of lower extremities. .perception disorders. .botox injection in the lower extremity in the past 6 months. .lower extremity surgery within the past 6 months.

Keywords: leg pedalling
prognostic impact of surgical resection extent for supratentorial high grade gliomas.

Conditions: Supratentorial Glioblastoma

Summary: prospective randomized controlled clinical trials (single arm study) of surgical treatment modalities for supratentorial high grade gliomas within the next two years.

supratentorial high grade gliomas are for surgical resection in any case according to many factors. investigators will compare the outcomes/survival rate and clinical outcome of the different resection types (total, near total, subtotal/debulking) of supratentorial high grade gliomas according to the clinical condition and comorbidities of the patient, the location and morphology of the lesion, the grading of lesions, and the clinical experience of the neurosurgeon.

Eligibility criteria:
inclusion criteria: * patients who will undergo surgical excision of the supratentorial high grade gliomas at the time of study (two years). * denovo disease for the first time. * any age exclusion criteria: * low-grade gliomas. * infratentorial high-grade gliomas. * past history of gliomas. * patients who are unfit for any neurosurgical interventions. * patients who do not receive their adjuvant standard therapy.